Business
Omeros to Present GPR174 Data at Upcoming American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy
SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (Nasdaq: OMER) today announced an upcoming presentation entitled “Phosphatidylserine suppresses T cells through
About this update from Omeros Corporation
[{"type":"text","content":" SEATTLE--(BUSINESS WIRE)--\nOmeros Corporation (Nasdaq: OMER) today announced an upcoming presentation entitled “Phosphatidylserine suppresses T cells through GPR174, and co-inhibition of adenosine receptors and GPR174 synergistically enhances T-cell responses” at the American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy, which is being held November 17 - 20, 2019 in Boston, Massachusetts.\n\n\nMarc Gavin, Ph.D., Omeros’ Director of Immunology, will present the company’s new findings that phosphatidylserine, a product of cell stress and death that is abundant in the tumor microenvironment (TME), directly stimulates GPR174 and attenuates T-cell responses.\n\n\nAdenosine, another product of the TME, is well known to stimulate the same suppressive pathways through different GPCRs, and inhibition of both pathways—with adenosine receptor antagonists and with Omeros’ novel GPR174 inhibitors—results in maximal enhancement of T-cell function, which should translate to effective resistance to the immunosuppressive nature of the TME.\n\n\nThe data will also feature new findings from animal tumor models, which validate GPR174 inhibition for cancer immunotherapy.\n\n\nDesignated B45, the poster will be presented in Poster Session B on Tuesday, November 19, 4:30 p.m. to 7:00 p.m.\n\n\nAbout Omeros Corporation\n\n\nOmeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. In addition to its commercial product OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3%, Omeros has multiple Phase 3 and Phase 2 clinical-stage development programs focused on complement-mediated disorders and substance abuse, as well as a diverse group of preclinical programs including GPR174, a novel target in immuno-oncology that modulates a new cancer immunity axis recently discovered by Omeros. Small-molecule inhibitors of GPR174 are part of Omeros’ proprietary G protein-coupled receptor (GPCR) platform through which it controls 54 new GPCR drug targets and their corresponding compounds. The company also exclusively possesses a novel antibody-generating pla...